---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000411"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:38:13.378275+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mirum reports FY 2022 LIVMARLI net product sales of $75.1M; Q4 sales up 48% QoQ

## Summary
- Full year 2022 LIVMARLI net product sales $75.1M (vs $3.1M in 2021); total revenue $77.1M.
- Q4 2022 net sales up 48% vs Q3 2022; U.S. business guided for 50% growth in 2023.
- Operating expenses $208.3M for 2022 (up from $192.6M in 2021); cash & investments $251.7M.
- sNDA submitted for LIVMARLI in PFIC; data milestones in biliary atresia (H2 2023) and volixibat programs.
- Capital raises net $121.9M since Jan 2022; net royalty obligations reduced via Satiogen acquisition.

## SEC filing metadata
- accession: 0001157523-23-000411
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000115752323000411/0001157523-23-000411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000115752323000411/a53358541.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000411
- JSON: https://secwatch.observer/filing/0001157523-23-000411.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.